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Advanced fabrication approaches to controlled delivery systems for epilepsy treatment 
 
ABSTRACT 
Introduction: Epilepsy is a chronic brain disease characterized by unprovoked seizures, which 
can have severe consequences including loss of awareness and death. Currently, 30% of 
epileptic patients do not receive adequate seizure alleviation from oral routes of medication. 
Over the last decade, local drug delivery to the focal area of the brain where the seizure 
originates has emerged as a potential alternative and may be achieved through the fabrication 
of drug-loaded polymeric implants for controlled on-site delivery.  
Areas covered: This review presents an overview of the latest advanced fabrication techniques 
for controlled drug delivery systems for refractory epilepsy treatment. Recent advances in the 
different techniques are highlighted and the limitations of the respective techniques are 
discussed.   
Expert opinion: Advances in biofabrication technologies are expected to enable a new 
paradigm of local drug delivery systems through offering high versatility in controlling drug 
release profiles, personalized customization and multi-drug incorporation. Tackling some of the 
current issues with advanced fabrication methods, including adhering to GMP-standards and 
industrial scale-up, together with innovative solutions for complex designs will see to the 
maturation of these techniques and result in increased clinical research into implant-based 
epilepsy treatment.  
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Article Highlights   
• Implantable polymeric drug delivery systems (DDSs) have gained a lot of interest due 
to their potential ability to treat refractory epilepsy by delivering drugs to the focus area.   
• A variety of drug release profiles can be tailored using electrohydrodynamic means to 
produce micro- and nano-scale particulate and fibrous structures, particularly through 
the inclusion of a core-shell configuration within the structures.  
• Three-dimensional (3D) printing is particularly suitable for DDS fabrication. It enables 
3D distribution of drugs and polymer matrix into complex geometries in a controlled 
manner, which can also be tailored to meet individual patient needs. 3D printing may 
offer solutions to some of the bottlenecks in epilepsy treatment that are not possible with 
conventional fabrication methods. 
• Various 3D printing techniques are compared, through examples of implant-based drug 
delivery applications, to explore the advantages and limitations of each technique. 
• Current challenges and future perspectives for advanced fabrication techniques in drug 
delivery for epilepsy treatment are discussed.   






Epilepsy is one of the most prevalent chronic brain diseases affecting approximately 1% of the 
worldwide population. Even if it is regarded as a consequence of a heterogeneous group of 
disorders underlying brain dysfunction, epilepsies share the hallmark feature of recurrent 
unprovoked seizures, which can cause loss of awareness, injury, psychosocial disability and 
even mortality  [1, 2]. Anti-epileptic drugs (AEDs) provided via an oral route still remain the 
mainstay of epilepsy treatment, though this method only achieves a satisfactory result with 
seizure control in approximately 70% of the patients. The remaining patients are unable to 
achieve sufficient seizure alleviation. The phenomenon of unresponsiveness to oral 
administration seems to be multifactorial, but there is significant evidence suggesting that the 
blood-brain-barrier (BBB) plays an important role [3]. The BBB segregates blood and brain 
interstitial fluid and protects the brain from harmful compounds circulating in the bloodstream. 
A key structure of the BBB is the formation of high-resistance tight junctions by brain vascular 
endothelial cells. These tight junctions only allow low molecular weight liposoluble molecules 
to cross the cerebral microvasculature barrier.  
 
One of the typical problems of current pharmacotherapy of epilepsy is that most AEDs have a 
relatively short half-life and need to be taken every day, usually more than once/day, even with 
extended-release preparations. It has been demonstrated that prolonged AED administration 
can cause agonist-induced receptor desensitization and/or internalization which results in 
reduced pharmacological efficacy [4, 5]. Furthermore, multiple drug transporters, which 
decrease AED concentration in the focus [6] may play a role in refractory epilepsies. This drug 
resistance leads to increasing doses of often multiple agents, and the high level of AEDs in the 
body often leads to intolerable systemic side effects which significantly impair the patients 




After failure of oral therapy with at least two AEDs, surgical resection of the dysfunctional 
brain can be considered in case of focal seizures. The success of the procedure highly depends 
on the affected brain region and varies from 25% for extra-hippocampal seizure to 70% in 
patient-specific seizures. However, surgical resection is inappropriate for seizure focus in 
deeper brain areas [8].  
 
Over recent years a range of new strategies have been attempted to increase the penetration and 
persistence of AEDs in the brain parenchyma, including drug delivery systems for systemic 
delivery [9] , prodrugs [10], efflux pump inhibitors [11], hyperosmolar BBB opening [12] and 
local drug delivery to circumvent the BBB [13, 14] , as well as gene and cell therapies [15]. 
Amongst these methods, one promising approach is local drug delivery directly to the area of 
the epileptic focus, which provides a high concentration of the drug available at the desired 
target, while minimizing toxic effects on the surrounding neuronal network. With ongoing 
progress in polymer science and advanced fabrication, polymeric implantable devices that are 
capable of controlled and sustained release of AEDs directly to the seizure focus are regarded 
as potential candidates in the treatment of refractory epilepsy (Table 1). 
  
The objective of this article is to summarize current approaches of advanced fabrication 
technologies for development of local drug delivery systems (DDSs) with a focus on the 
potential of 3D printing for future treatment of epilepsy.  
 
2. Processable polymers for controlled drug delivery 
The range of processable materials compatible with applications in drug delivery has constantly 
expanded over the years. Among them, polymers are one of the most intensively explored 
materials. Polymers can be classified as non-biodegradable and biodegradable. Drug release 
from a non-biodegradable polymeric matrix is mostly characterised by passive diffusion. In 
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contrast, drug delivery from a biodegradable polymer matrix can be mediated by both diffusion 
and degradation. Biodegradable polymers can be divided into synthetic or naturally-derived 
polymers. A typical class of synthetic biodegradable polymers that are commonly used in 
epilepsy treatment are aliphatic polyesters like (polylactic acid) (PLA) [16], poly (lactic-co-
glycolic acid) (PLGA) [17-20] and poly(ɛ-caprolactone) (PCL) [21, 22]. Compared to 
naturally-derived polymers, such as silk fibroin [23],  these synthetic materials are 
commercially available in a variety of composition and molecular weight. While most of the 
natural polymers undergo enzymatic-degradation, these synthetic biomaterials undergo 
polymer erosion through the cleavage of hydrolytically sensitive bonds. Early investigations of 
these biomaterials showed superior biocompatibility [24, 25]. Degradation of these 
biodegradable polymers depends on a number of parameters, including molecular weight, 
polydispersity, crystallinity and polymer composition [25]. In general, the degradation process 
of these polymers can be classified into bulk and surface erosion which has significant influence 
on the drug release kinetics [26]. Bulk erosion refers to a homogenous erosion of the structure 
when the water penetration is faster than the polymer degradation, while surface erosion 
addresses a heterogeneous erosion when degradation of the polymer is faster than the water 
penetration. Based on the different erosion mechanisms, drug release from these biomaterials 
can be roughly divided into (i) diffusion controlled, (ii) swelling controlled, and (iii) erosion 
controlled mechanisms [27]. An interesting example in the group of aliphatic polyesters is 
PLGA, which is a copolymer consisting of lactic acid and glycolic acid and shows degradation 
behaviour dependent on the monomer composition. The rate of degradation decreases with the 
rate of lactic acid to glycolic acid up to 6 months. As an exception to this rule, when the ratio 
of lactic acid and glycolic acid is 50/50, the rate of degradation is the fastest with approximately 




In terms of local treatment of epilepsy, early work in the polymer-based DDSs were focused on 
monolithic implants such as pellets, disks or rods, using non-biodegradable polymers [30]. The 
drawback of these non-biodegradable brain implants is the need for additional surgeries to 
remove the implant once the drug is fully eluted, but this introduces risk of intracranial 
infections or neurological deficits. More recently researchers explored the possibility of 
biodegradable polymers for the treatment of refractory epilepsy to avoid the need of resective 
surgeries [31]. Unfortunately, these studies have failed to provide sustained long-term release 
of AEDs. This could be addressed by recent advancements of fabrication techniques that enable 
the processing of complex polymer structures through more controlled and precise deposition 
of polymeric materials and drugs. 
  
3. Micro- and nanoparticle formulations 
Epilepsy is a diverse disease with multiple seizure types of many epileptic syndromes. In 
general, there are two major classes of epilepsy: focal seizures, in which the epilepsy focus 
appears at a cortical site, and generalized seizures, in which the neuronal disorder is distributed 
in both hemispheres of the cortex. Depending on the seizure onset different therapeutic 
strategies need to be considered. For the treatment of focal epilepsy, where often the seizure 
focus is in deeper brain areas such as the hippocampus, monolithic implants are unsuitable due 
to low accessibility. Novel particulate formulations in the form of micro- or nanospheres, which 
can be injected into the brain parenchyma, represents as a promising approach for the treatment 
of epilepsy. A great variety of techniques have been developed for the fabrication of particle 
formulations. In principle these methods can be roughly divided into chemical processes (e.g. 
in situ polymerization), physico-chemical processes (e.g. sol-gel encapsulation) and physio-
mechanical methods (e. g. spray drying and solvent evaporation) [32]. Amongst these methods, 
physio-mechanical techniques have been most intensively explored for fabrication of DDSs for 
epilepsy treatment. The majority of the studies have been undertaken primarily to improve 
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bioavailability of oral administration [33], limited studies have been focused on local delivery 
through intracranial injection. 
 
Emulsification solvent evaporation (ESE) is a facile approach for encapsulation of 
pharmaceutical compounds (Figure 1A). For encapsulation of hydrophobic drugs, a common 
approach is through oil-in-water (O/W) emulsion, where a polymer matrix and target drug are 
dissolved in an organic phase comprising volatile solvent such as dichloromethane or 
chloroform, and then dispersed into an aqueous phase. Subsequent evaporation of the organic 
solvent results in formation of drug-loaded microspheres [32]. For encapsulation of hydrophilic 
drugs, one popular approach is through water-in-oil-in-water (W/O/W) double emulsion 
(Figure 1B). An aqueous drug-loaded phase (W1) is emulsified into a polymer containing oil 
phase (O1), which is then further emulsified in a second water phase (W2) to produce drug-
loaded oil droplets and microspheres upon removal of the organic solvent [34].  
 
Investigations have shown that injectable particle formulations of diazepam (DZP) and 
phenytoin (PHT) exhibit sustained release in-vitro as well as efficacy in-vivo. DZP was 
encapsulated in poly(hydroxybutyrate-hydroxyvalerate) (PHBV) microspheres, and a triphasic 
release pattern was observed in vitro over a period of 30 days [35]. PHBV-microspheres showed 
a burst release of approximately 20% to 42% during the first day, followed by more linear 
controlled drug elution about 18 days. The third stage was characterised by steady state for 
approximately 12 days until the conclusion of the study at 30 days. The efficacy of PHT-PCL-
microspheres to successfully suppress seizures was demonstrated by Jiang et al.[21] by 
injection of the microspheres into the hippocampus of a rat tetanus model of temporal lobe 
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epilepsy. Compared to the controls, the PHT-loaded microspheres demonstrated a one-third 
reduction in seizure events in vivo during the period of drug release.  
 
Spray drying involves injection of a fluidic feed into a hot drying medium [36] (Figure 1C). 
The fast injection results in evaporation of the volatile compound and initiates a liquid-solid 
transition [37]. For fabrication of a DDS, depending on the solubility of the target drug and 
polymer matrix, a feed for spray drying can be a drug-loaded polymer solution (for a 
hydrophobic drug), or an emulsion (for a hydrophilic drug). In the latter case, the drug is 
dissolved in an aqueous phase and then emulsified in a polymer solution for spray-drying [16]. 
Particle formulations prepared by spray-drying were investigated in vitro for delivery of DZP 
[17], clonazepam [38] or PHT [22]. For instance, a recent work by Li et al. showed that PHT 
release from the spray-dried PCL microcarriers followed a multi-stage pattern [22]. PHT release 
followed a multi-stage pattern. For the first 4 days, PHT-release was linear, followed by a 
decreased release rate for the next 8 days before reaching 80% of completion after 21 days.  
 
Recently, electrospraying, also known as electrohydrodynamic atomization, has emerged as  a 
powerful tool for fabrication of drug-loaded microparticles [39] (Figure 1D). A liquid polymer 
solution is injected to a nozzle and subjected to a high electric field. When the electrostatic 
repulsion surpasses the surface tension of a liquid droplet, ejection of the polymer solution will 
occur at the surface of the droplet and subsequently break off to form microdroplets. 
Electrospraying shows great potential for drug delivery due to the ability to fabricate 
monodisperse microparticles, and composite microparticles with core-shell morphology. The 
latter is achieved using a coaxial nozzle, and offers a number of advantages including improved 
drug stability and better control of drug release kinetics and ease of loading of multiple drugs, 
as is compared to the monoaxial electrospraying approach. For instance, Wang et al. reported 
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a type of PLLA core-PLGA shell microparticles for dual growth factor delivery [40]. Sequential 
release was achieved by electrojetting simultaneously FGF-2/core phase emulsion and BMP-
2/shell phase emulsion at a specific ratio though a coaxial needle. Chen et al. reported the 
preparation of core-shell structured PLGA-microcapsules loaded with anti-convulsive 
lacosamide by coaxial-electrospraying [41]. The release-profile of lacosamide varied 
significantly with the shape and morphology of the resultant core-shell DDS. Microflakes 
showed fast release behaviour, with over 96% of their drug payload released within 2 days. 
Compared to the microflakes, drug-release from the microspheres offered slower drug elution 
with approximately 70% of their drug payload released within 2 days and a less initial burst 
release. After 11 days the microspheres released over 90% of their drug payload. However, 
future studies are needed to improve on the efficacy of these formulations in vitro and in vivo, 
by optimising the core and shell structure design in terms of structural composition and 
respective thickness.   
 
4. Electrospinning 
Electrospinning is another electro-hydrodynamic processing method, which has been 
intensively employed to produce micro/nanofibrous structures for a broad range of biomedical 
applications [42, 43]. Similar to electrospraying, a typical electrospinning process involves 
injection of a polymer solution through a nozzle under a high electric field. The polymer 
solution at the tip of the spinneret forms a droplet. When the viscosity of the polymer solution 
is above a threshold, the ejected solution will not break down as microdroplets, resulting in 
continuous ultrathin fibres on the collector plate.  
 
A facile approach to encapsulate pharmacological compounds into electrospun fibres is by 
dissolving target drug. Drug release from these devices are highly dependent on the distribution 
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of the drug in the electrospun fibres. Thus, the hydrophobic-hydrophilic properties of drug and 
polymer should be matched [44]. However, drug release from electrospun fibres prepared by 
dissolution of the drug into the polymer solution demonstrates a high burst release caused by 
the relatively high surface area to volume ratio of the fibre. To solve this issue, composite fibres 
with a core-shell morphology have been developed to reduce the initial burst release (Figure 
2A). Zhang et al. demonstrated that the initial burst of fluorescein isothiocyanate (FITC)-
labelled BSA from the PCL cores was significantly reduced by the polyethylene glycol (PEG) 
shells when compared to the structure without the PEG shells [45]. The efficacy of coaxially 
electrospun PLGA fibres to ameliorate seizures, where lacosamide was encapsulated only in 
the core, were reported by Bauquier et al. [23]. The PLGA fibres showed sustained elution of 
lacosamide over a period of 90 days in vitro. Subdural implantation of the lacosamide-loaded 
fibres above the motor cortex in a Genetic Absence Epilepsy Rat model demonstrated to 
significantly reduce the duration of spike-and-wave discharges (SWD) for up to 7 weeks. 
 
Emulsion electrospinning technique refers to simultaneous spinning of two immiscible 
solutions to incorporate hydrophilic drugs. An aqueous solution of the drug is emulsified into 
an organic solution in which the fibre-forming polymer is solubilized. Due to the viscosity 
gradient, formed by the evaporation of the volatile solvent, aqueous droplets migrate to the 
centre of ejected fibres and unify [46]. Recently, Viry et al. reported the preparation of 
levetiracetam (Lev)-containing electrospun fibres. Lev-loaded fibres were prepared using a 
coaxial- and coaxial/emulsion-based electrospinning setup (Figure 2B and C), respectively 
[18]. Compared to the coaxial fibers, the in vitro release of Lev from the emulsion/coaxial fibres 
demonstrated a nearly linear, much more sustained release pattern for at least 18 days (Figure 
2D).  
 
5. 3D printing  
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Three-dimensional (3D) printing is a subset of additive manufacturing, which involves 
fabrication of a 3D object by depositing successive layers of material in a defined spatial 
arrangement according to a computer aided design (CAD) model. Since its original discovery 
by Charles Hull in 1986, 3D printing has been used as a cost-effective, rapid prototyping 
technique with a wide range of applications in e.g. aerospace, construction, medical and 
jewellery. In particular, 3D printing is highly suitable for small scale productions, including 
customization and personalized manufacturing while allowing for complex designs, normally 
difficult to fabricate with more conventional manufacturing methods. Additionally, fabrication 
approaches described previously rely on the use of organic solvents during processing. Residual 
organic solvents, such as methylene chloride which is suspected to be carcinogenic and 
mutagenetic, implies a health risk for patients and is strictly regulated by regulatory agencies. 
3D-printing approaches offers the possibility to process in a solvent-free fabrication mode. 
These benefits have allowed the steady growth of 3D printing and other additive manufacturing 
techniques in biomedical applications, from (bone) tissue engineering to printing of anatomical 
models, over the last 30 years [47-49]. 
 
Pharmaceutical applications of 3D printing are still in the relative early stages, and only recently 
has there been attention directed towards the fabrication of DDSs with 3D printing. This 
culminated in the approval of Spritam® (levetiracetam), the first 3D printed orodispersible 
tablet with FDA approval, in 2016. Although the approval shows the potential of 3D printing 
for tablet-based DDSs for epilepsy, part of the focus has shifted towards the fabrication of 
implant-based systems [31, 50]. A schematic depiction of the different 3D printing techniques 
used in pharmaceutical manufacturing can be found in Figure 3. The next sections will describe 
in more detail the different printing techniques used for drug delivery implant fabrication and 
highlight some potentially useful articles that, although not using antiepileptic agents as the 




5.1 Fused Deposition Modelling (FDM) 
FDM is a technique in which thermoplastic polymers are extruded as filaments through a 
nozzle-based system. The polymer is mechanically pushed past a heating block, of which the 
temperature can be tuned depending on the melting temperature of the desired polymer, and as 
a result the polymer gets liquefied. Upon deposition onto the build plate the polymer cools down 
and solidifies, allowing for a relatively precise spatial arrangement in the deposition. Some of 
the more commonly used polymers with FDM are acrylonitrile butadiene styrene (ABS), PLA, 
PCL and ethylene-vinyl acetate (EVA) [51]. However, ABS is rarely used in pharmaceutical 
3D printing due to its low biodegradability and high toxicity [52]. FDM has widely been used 
for the fabrication of tablet-based DDSs, but more limited research has been conducted on 
implants with drug delivery capabilities. 
  
An implant for contraceptives has been manufactured by Genina et al. [53] using EVA 
copolymers. They investigated a range of different concentrations of vinyl alcohol and were 
able to successfully fabricate custom T-shaped intrauterine systems and subcutaneous rods with 
drug delivery capabilities. However, rigorous optimisation is required for each new drug-loaded 
and drug-free feedstock for FDM, as a main limitation of this technique is that the drugs usually 
have to go through the whole material fabrication process, often requiring high temperatures or 
toxic chemicals. A recent study by Visscher et al. [54] evaded this issue through combining 
FDM printing with salt-leaching and as a result were able to introduce microporosity into the 
drug-loaded scaffold. By further coating this scaffold with gelatin methacrylate (GelMA) a 




Previous studies have been limited by the use of only a single type of polymer. For future 
developments of 3D printed implants, it is important to assess and compare different polymers 
and drug loads. Kempin et al. [55] used quinine as a model drug with 4 different polymers. The 
amount of drug released was highly dependent on both the polymer used and the drug load. 
Further research could establish correlations between a wide range of desired drug release 
profiles and the appropriate polymer and drug load to use. 
 
These applications show that FDM is a reliable, low-cost and efficient alternative technique for 
producing customizable shaped implants, and that long-term release profiles are possible. 
However, the degradability of specific drugs at the high temperatures used should be taken into 
careful consideration and problems might occur when switching to different polymers and/or 
drugs. Particularly, exploration of a combination of FDM and other techniques to prevent drugs 
from degradation by the fabrication process could provide opportunities for novel drug/polymer 
combinations.  
 
5.2 Extrusion-based printing 
Extrusion-based printing employs a pneumatic-, mechanical- or solenoid-based system to 
deposit materials from a nozzle in a layer-by-layer fashion onto a build plate to create a 3D 
construct. Mostly viscous and semi-liquid materials are used in this method, with the viscosity 
and viscoelastic properties of the materials being vital for their printability. A pioneering 
approach has been reported utilizing a custom liquid extrusion-based printer for the fabrication 
of a DDS with relative long-term release profile [56]. Two types of liquid ink materials, 
dexamethasone-loaded polyvinyl alcohol (PVA) solution and poly(lactic-co-glycolic acid) 
(PLGA), were employed to print a construct with dexamethasone-PVA located in the core 
(Figure 4A and B). By changing the thickness of the construct through addition of extra layers 
of PVA and PLGA in a sandwich-like structure a sustained drug release of up to 4 months was 
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achieved. Although PCL and PLGA are popular materials to use with this technique, a study 
by Holländer et al. [57] showed the versatility of extrusion-based printing by using 
polydimethylsiloxane (PDMS), which previously had not been used for the fabrication of 
DDSs. They were able to fabricate 3D-printed drug-loaded PDMS constructs with drug-release 
profiles of prednisolone for at least 28 days.    
 
By employing a coaxial set-up using air-powered and mechanically-powered extrusion of 
alginate and CaCl2, respectively, Do et al. [58] fabricated a DDS with a core-shell structure. 
The construct was shown to be non-cytotoxic and different fluorescent dyes were used to mimic 
drug release profiles. To note, although the alginate-PLGA tubes show high mechanical 
strength, incorporation of drugs decreases the overall mechanical properties and thus would 
need minor adjustments to improve the strength to a suitable level for implant-based 
applications. On the other hand, Song et al. [59] were able to achieve proper mechanical 
properties by combing a drug-loaded PLGA hydrogel with a PCL-based polymeric framework 
for extra stability. This carrier allowed for sustained local delivery of cyclosporin A and a 
resulting reduction in a xenogeneic cell-based immune response. Extrusion-based printing of 
hydrogels has potential to be applied for local AED delivery because hydrogel-based DDSs 
have been shown to provide site-specific, sustained delivery to brain tissue [60, 61]. 
Furthermore, polymer hydrogel systems are mechanically compliable with the  soft CNS tissue 
[62].  
 
5.3 Stereolithography (SLA) 
SLA is based on a photopolymerization process, where typically a UV laser is used to produce 
a specific pattern according to the accompanying CAD design and via layer-by-layer curing of 
ink materials (monomers or polymer precursors). Traditionally, SLA is not suitable for drug 
manufacturing because of the scarcity of biocompatible/biodegradable photopolymerizable raw 
15 
 
materials used in pharmaceutical manufacturing and the toxic effects of some uncured material 
and free radical formation [63, 64]. More recently, research employing SLA for DDS 
applications produced systems including a topical patch [65], transdermal micro-needles [66] 
and tablet forms [67]. However, to the best of our knowledge no implant-based application has 
been explored for this technique. Potential advantages of this technique would be the superior 
resolution and accuracy compared to other conventional fabrication techniques [67, 68]. 
Additionally, the UV photo polymerization has shown little effect on drug degradation, 
allowing the encapsulation of thermally labile drugs due to the minimization of localized 
heating [69].   
 
5.4 Binder jetting 
Binder jetting, in some cases referred to as 3DP, is a printing technique in which a liquid is 
deposited onto a powder bed. The layer of powder is spread out onto the build plate via a roller 
after which the liquid binding material is jetted onto the powder bed. This binds the powder 
together and results in an object being produced by the agglomeration of multiple layers stacked 
on top of each other forming dense powder compacts. It is similar to conventional powder tablet 
manufacture in material composition, but the binder jetting technique can create highly porous 
structures for rapid disintegration and quick drug release. The previously mentioned drug 
Spritam®, is produced in this manner. One of the first implant applications of this technique 
was by Lin et al. [70] who fabricated sub dermally implantable DDSs with a drug release of 
five weeks in one of their designs. Various other groups have used binder jetting to produce 
implants with antibiotics loaded in, either singular [71, 72] or with multiple drugs [73, 74]. 
Overall, the implants produced have a relative moderate duration of drug release, continuously 
releasing for over 6 weeks [74]. More recently, Wu et al. [75] produced a cylindrical shaped 
drug releasing implant incorporating levofloxacin and tobramycin in a specific sequence 
(Figure 4C and D). Although drug loading was relatively low in this study due to the dispersion 
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of the drug in the solution, a sustained release was achieved for at least 50 days. In all, an 
advantage of using binder jetting for potential AED delivery applications is that implants can 
have highly defined micro- and macro-porosities to allow for complex multi-drug release 
profiles. Still, it is important to establish different material and drug combinations on a case-
by-case basis, as the efficacy can be affected by the manufacturing process significantly.    
 
5.5 Selective laser sintering (SLS)  
SLS uses a powder bed as the base material, similar to the previously mentioned binder jetting 
technique. However, instead of using a liquid material, in SLS a laser binds the powder particles 
together. The laser is used to make a specific pattern on the powder bed, after which new powder 
is rolled on top of the previous layer and a new pattern is created. An interesting advantage for 
this technique compared to some of the other advanced fabrication techniques is that it does not 
require a solvent, which could potentially be harmful or degrade drugs encapsulated inside. On 
the other hand, the use of a laser results in tough printing conditions, mainly due to the high 
temperatures and high-energy laser required. This can lead to the degradation of drugs 
contained in the powder bed [76]. Originally, the only DDSs produced with this technique 
loaded the drug after the printing process [77, 78]. Recently Fina et al. [79] showed a proof-of-
concept for using SLS to produce a tablet form DDS with two different polymers by utilising 
excipients to protect the loaded drug from degradation.  
 
Table 2 shows the advantages and disadvantages associated with the different 3D printing 
techniques previously discussed. As may be evident, each technique is vastly different and 
choosing the appropriate technique for each application is critical. Clearly some techniques, 
e.g. FDM and extrusion-based printing, have been explored more in the context of implant-
based DDS fabrication and could thus be more suited for future implant-based epilepsy 
treatment research. Particularly the latter seems to be well-suited for AED release applications, 
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considering the potential of hydrogels for drug delivery in brain tissue and the validation of 
extrusion-based printing for implantable DDS, although in a different application, in both an in 
vitro and follow-up in vivo mouse model study [80, 81].   
 
6. Expert opinion  
The versatility of the advanced fabrication techniques described in this review show the exciting 
new possibilities for development of DDSs that can contain multiple drugs with variable release 
profiles within the same system. This exceptionally high degree of flexibility and control are 
optimally suited for pharmaceutical manufacturing because of the need for customized, 
complex and innovative DDSs. The different methods of fabrication are expected to support 
new developments of implants for personalizing drug therapy to address intricate dosing 
regimens and patient specific needs. It is clear that there is not a one-method-fits-all solution to 
drug products, but rather that each problem requires a solution encompassing different 
techniques and material compositions. With constant research into novel advanced fabrication 
methods it will be possible to engineer the desired technique and material from a certain 
objective for the amount of drugs released, the release profile and degradation of the material 
used. With the end goal in mind, an important focus of future research should be to translate 
the advantages of these described techniques into tangible benefits for the patient. 
 
However, there are a range of issues that will need to be addressed before industry acceptance 
of these techniques including quality control, GMP-compliance, throughput scale-up, among 
other legal, regulatory and administrative issues. Another important focal point is the need to 
identify novel compatible materials alongside exploration of new technologies. 
 
The wide range of techniques discussed herein have been used to produce implant-based DDSs 
for a wide variety of medical applications but have scarcely been applied towards epilepsy 
18 
 
treatment. This is partly due to the ongoing exploration of the full spectrum of capabilities of 
these techniques. Furthermore, a primary focus of some novel techniques is proving the efficacy 
of different materials using model drugs as a proof-of-concept, rather than exploring the 
versatility of the implant for different applications. As research into implantable DDS 
intensifies, and with the recognition of their potential and the amount of research increasing 
into fabricating DDS for epilepsy treatment with more conventional methods, it is expected that 
the research into advanced fabrication methods for anti-epileptic implantable devices will 
increase concurrently.  
 
It is evident that in the future, establishing new collaborations, both within academia as well as 
with industry partners and clinicians, will be vital for full integration into the industrial 
pharmaceutical manufacturing market. The further maturation of these techniques will result in 
an accelerated process from bench to bedside. A vital first step has already been taken with the 
approval of Spritam® and we expect more to follow in the coming years. Innovative solutions 
are needed to solve some of the inherent limitations of the various advanced fabrication 
techniques, in particular 3D printing, and combining different techniques for synergistic effects 
may be the approach of choice to overcome limitations of singular fabrication methods. 
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GMP = Good manufacturing process  
DDS(s) = Drug delivery system(s) 
3D = Three-dimensional  
AEDs = Anti-epileptic drugs 
BBB = Blood brain barrier  
PLA = Polylactic acid 
PLGA = Poly(lactic-co-glycolic acid) 
PCL = poly(ɛ-caprolactone) 
ESE = Emulsification solvent evaporation  
O/W = Oil-in-water 
W/O/W = Water-in-oil-in-water 
DZP = Diazepam 
PHT = Phenytoin  
PHBV = Poly(hydroxybutyrate-hydroxyvalerate) 
PEG = Polyethylene glycol  
SWD = Spike-and-wave discharges  
CAD = Computer aided design  
FDM = Fused deposition modelling  
ABS = Acrylonitrile butadiene styrene  
EVA = Ethylene-vinyl acetate  
GelMA = Gelatin methacrylate  
PVA = Poly-vinyl alcohol  
PDMS = Polydimethylsiloxane  
SLA = Stereolithography  
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Table 2: Advantages and disadvantages of the printing techniques employed for implantable 
DDS fabrication 
Abbreviations: FDM – Fused Deposition Modelling, SLA – Stereolithography, DDS – Drug 







       Advantages        Disadvantages 
FDM • Simple and low-cost 
• Versatility in scale 
(industrial and laboratory) 
• Good mechanical 
properties 
 
• High temperature usually 
required for printing 
• Complex geometries 




• Relative high resolution 
• Suitable for thermally 
sensitive drugs 
• Limited compatible 
materials available 
• Difficulties with multi-drug 




• Moderate cost 
• Easy incorporation of 
multiple materials/drugs 
• Moderate resolution 
 
 
• Low mechanical properties 
when using hydrogel-based 
materials for printing 
• Materials require certain 




• Relative fast printing at 
room temperature 
• High versatility through 
adjusting bulk material 







• Low resolution 
• Binding solution may result 
in bleeding (migration of 
liquid) resulting in 
heterogeneous DDSs 
• Post-printing process is 
required to remove residual 






• No solvent required 
• One-step process with high 
resolution 
• High-power lasers and high 
temperatures may be 
required for printing, 
resulting in degradation of 
drug 




Figure 1. Fabrication techniques of drug-loaded microspheres. (A) Single emulsion method 
for hydrophobic drugs, (B) Double emulsion method for hydrophilic drugs, (C) Spray drying 
and (D) Coaxial electrospraying. 
Figure 2. Fabrication of levetiracetam (Lev)-releasing microfibres consisting of 75:25 PLGA 
core and 85:15 PLGA shell. (A) Illustration of a typical coaxial electrospinning process. (B) 
Coaxial-setup, with the core composed of 75:25 PLGA/Lev solution in dichloromethane, and 
the shell composed of 85:15 PLGA in dichloromethane/dimethylformamide (70/30). (C) 
Emulsion-coaxial-setup with the core composed of 75:25 PLGA/Lev emulsion in 
dichloromethane, and the shell composed of 85:15 PLGA in 
dichloromethane/dimethylformamide (70/30). (D-I) SEM micrographs of the Lev-releasing 
microfibres: top view (D and E) and cross-section (F, G, H and I). (D and F) present the coaxial 
electrospun PLGA microfibers. (E, G, H and I) present the emulsion/coaxial electrospun PLGA 
microfibers. For emulsion-coaxial electrospinning, the dispersed-to-continuous phase volume 
ratio in the emulsion core is used to control the cavity size and diffusive length of the released 
system. A big volume ratio (1/5) (H) of the dispersed-to-continuous phase results in the 
formation of large cavities (line arrow) and short diffusive lengths (dash arrow). In contrast, a 
much lower ratio (1/55) (I) results in smaller cavities (line arrow) and larger diffusive 
membranes (dash arrow). Scale bars are 1 µm. (J) In vitro release of Lev from the coaxial (□) 
and emulsion/coaxial (◊) PLGA electrospun fibres. Drug amount (Mt) released relative to drug 






Figure 3. Schematic representation of commonly used 3D printing techniques employed for 
drug delivery. (A) Fused-Deposition Modelling, (B) Extrusion-based printing, (C) 
Stereolithography, (D) Binder Jetting and (E) Selective Laser Sintering. Adjusted with 
permission from Mota et al. [49] 
 
Figure 4. Implantable drug delivery systems with complex geometries. (A) Schematic depiction 
of the side view of dexamethasone-loaded PVA within PLGA in a 1 layer and 2 layer set-up. 
(B) Drug release profiles of dexamethasone from different layer scaffolds. Adapted with 
permission from [56]. (C) Three-dimensional perspective and longitudinal section of an implant 
with multiple drugs included (layer 1 and 3 contained rifampicin (RFP) and layer 2 and 4 
contained isoniazid (ISH)). (D) In vitro release profiles of INH and RFP. Adapted with 
permission to be obtained from [73]. 
